Given its role in different BCR-induced signalling pathways, it is not surprising that knockdown and pharmacological inhibition of PKCβ suppresses chronic BCR-signalling in the ABC-subtype of DLBCL [43] and cell proliferation [37]. Here, PRKCB is linked to diffuse large B-cell lymphoma.